Company intelligence / Profile preview

Allogene Overland Biopharm

Shanghai, Shanghai Shi, Chinaallogene.com ↗

Ownership: Private
Development stage: Other

Overview

Allogene Overland is a joint venture focused on developing, manufacturing, and commercializing allogeneic CAR T cell therapies for cancer patients across Greater China, Taiwan, South Korea, and Singapore. The company holds exclusive rights to develop four key allogenic CAR-T candidates targeting BCMA, CD70, FLT3, and DLL3. Several programs are in preclinical or early clinical phases as of 2025. The parent companies have demonstrated promising results with these modalities globally but local pivotal data is pending.

Therapeutic areas: Oncology
Modalities: Allogeneic CAR T cell therapies
Industry: Biotech

Partnerships

Joint venture between two major biotechs—Allogene Therapeutics Inc. and Overland PharmaceuticalsBacked by Hillhouse Capital via the involvement of Overland Pharmaceuticals

Beyond the preview

Go deeper on Allogene Overland Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Allogene Overland Biopharm.